Laurent Audoly

Founder & CEO Parthenon

Laurent Audoly is a serial biotech entrepreneur and senior executive in the biotech/pharma industry. He has contributed to the identification and development of 7 novel approved medicines addressing unmet medical need across multiple disease areas generating > $2B in annual sales. He is the CEO & founder of Parthenon Therapeutics, a precision oncology biotech operating at the intersection of systems biology, machine learning, pharmacology, and drug development to beat recalcitrant cancers. He also serves as an independent board member (Cytovia Therapeutics, Vanderbilt University). Prior to Parthenon, Laurent was at the helm of Kymera as its founding CEO. Earlier in his career, he held positions of increasing leadership responsibilities at Pfizer, Merck, and biotechs contributing to the advancement of 21 drug candidates into and trough clinical development. Laurent has completed pharma/biotech worth over $3B in biobucks and raised > $250M. He is an inventor and authored over 70 papers and patents. He studied chemistry and pharmacology (Ph.D.) at Vanderbilt University and was the recipient of an American Heart Association Fellowship at Duke University.